Work

A phase I/II study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress.

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.6_suppl.tps182

Authors: Justin Shaya, Wanling Xie, Biren Saraiya, Mamta Parikh, Edmund Folefac, Adam C. Olson, Atish Dipankar Choudhury, David Johnson Einstein, Elisabeth I. Heath, Rahul Atul Parikh, Charles Kunos, S. Percy Ivy, Patricia LoRusso, Razelle Kurzrock, Geoffrey Shapiro, Rana R. McKay

Institutions: Moores Cancer Center, Dana-Farber Cancer Institute, Rutgers Cancer Institute, UC Davis Comprehensive Cancer Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Duke University, Duke Medical Center, Beth Israel Deaconess Medical Center, Wayne State University, The Barbara Ann Karmanos Cancer Institute, The University of Kansas Cancer Center, Summa Health System, National Institutes of Health, National Cancer Institute, Yale University

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3134983840

Cites:

Cited by: 9

Related to: 10